Unfortunately, resistance to venetoclax develops by several distinct mechanisms, including mutations in BCL2, epigenetic pathways, alterations in oxidative phosphorylation, alterations in BCL2 pathway, tumor microenvironment, genetic heterogeneity, and Ritcher’s transformation. Here, BCL2 is linked to neoplasm.